OptiBiotix Health PLC SlimBiome® receives approval from FSSAI in India (8084V)
11 Abril 2019 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 8084V
OptiBiotix Health PLC
11 April 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
SlimBiome(R) receives approval from FSSAI in India
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, cardiovascular disease and
diabetes, announces that, further to the previous announcement made
on 7 January 2019, it has received a licence from the Food
Standards and Safety Authority India ("FSSAI") for its award
winning weight management product, SlimBiome(R) to be manufactured
in India. The approval was gained by OptiBiotix's manufacturing
partner, Zeon Life Sciences, for both SlimBiome(R) and SlimBiome(R)
containing products.
FSSAI licence approval involves both ingredient and quality
verification to ensure the product and manufacturing process is of
a high standard and is an essential regulatory requirement to
manufacture and distribute food products in India. The licence
approval allows Zeon to fulfil orders arising from OptiBiotix's
recent visit to India for SlimBiome(R) and SlimBiome(R) containing
products in its own manufacturing site.
This is a strategic step by OptiBiotix to add manufacturing in
Asia to the supply chain and extend the market opportunity for its
patented award winning weight management product into the fast
growing Indian market with an established partner. Zeon include
major Indian and international healthcare companies such as Danone,
GNC, Decathlon, Sun Pharma and Herbalife amongst its customers and
was awarded Nutraceutical Manufacturing Company of the Year in 2017
by The Associated Chambers of Commerce and Industry of India.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are really
pleased that Zeon has received FSSAI approval to manufacture
SlimBiome(R) in India. This allows them to fulfil partner orders
and meet the needs of other partners interested in selling
SlimBiome(R) and SlimBiome(R) containing products in India. We have
been really impressed with the professionalism of Zeon and the
speed at which they are creating interest and orders for our
products in India. Achieving FSSAI approval so quickly is a
significant achievement and is an important step in completing the
supply chain to meet the needs of existing and new corporate
partners in India and Southern Asia. This agreement is another step
in a strategy designed to build multiple revenue streams from
ingredient sales, and white label and own label branded consumer
and pharmaceutical products across multiple channels with industry
partners from around the world."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD)
Liam Murray / Jo Turner Tel: 020 7213 0880
finnCap (Broker)
Geoff Nash/ Scott Mathieson / Kate Bannatyne
(Corporate Finance) Tel: 020 7220 0500
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCZBLFFKZFFBBF
(END) Dow Jones Newswires
April 11, 2019 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024